IL155573A0 - Novel compounds for use as hiv protease inhibitors - Google Patents

Novel compounds for use as hiv protease inhibitors

Info

Publication number
IL155573A0
IL155573A0 IL15557301A IL15557301A IL155573A0 IL 155573 A0 IL155573 A0 IL 155573A0 IL 15557301 A IL15557301 A IL 15557301A IL 15557301 A IL15557301 A IL 15557301A IL 155573 A0 IL155573 A0 IL 155573A0
Authority
IL
Israel
Prior art keywords
protease inhibitors
novel compounds
hiv protease
hiv
inhibitors
Prior art date
Application number
IL15557301A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL155573A0 publication Critical patent/IL155573A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15557301A 2000-11-22 2001-11-12 Novel compounds for use as hiv protease inhibitors IL155573A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028483.6A GB0028483D0 (en) 2000-11-22 2000-11-22 Hydroxyethylamine HIV protease inhibitors
PCT/EP2001/013068 WO2002042277A1 (fr) 2000-11-22 2001-11-12 Nouveaux composants servant d'inhibiteurs de protease vih

Publications (1)

Publication Number Publication Date
IL155573A0 true IL155573A0 (en) 2003-11-23

Family

ID=9903670

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15557301A IL155573A0 (en) 2000-11-22 2001-11-12 Novel compounds for use as hiv protease inhibitors

Country Status (27)

Country Link
US (1) US6472404B1 (fr)
EP (1) EP1339692A1 (fr)
JP (1) JP2004520283A (fr)
KR (1) KR20030060953A (fr)
CN (1) CN1476436A (fr)
AR (1) AR031763A1 (fr)
AU (2) AU2002229546B2 (fr)
BG (1) BG107839A (fr)
BR (1) BR0115566A (fr)
CA (1) CA2428459A1 (fr)
CZ (1) CZ20031667A3 (fr)
EC (1) ECSP034618A (fr)
GB (1) GB0028483D0 (fr)
GT (1) GT200100233A (fr)
HU (1) HUP0303007A2 (fr)
IL (1) IL155573A0 (fr)
MA (1) MA26966A1 (fr)
MX (1) MXPA03004534A (fr)
NO (1) NO20032290L (fr)
NZ (1) NZ525550A (fr)
PA (1) PA8533401A1 (fr)
PE (1) PE20020610A1 (fr)
PL (1) PL366704A1 (fr)
RU (1) RU2265016C2 (fr)
SK (1) SK7602003A3 (fr)
UY (1) UY27033A1 (fr)
WO (1) WO2002042277A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014572B (zh) * 2004-09-15 2011-07-06 盐野义制药株式会社 具有hiv整合酶抑制活性的氨基甲酰基吡啶酮衍生物
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
CA2719721C (fr) * 2008-03-26 2012-12-18 Daiichi Sankyo Company, Limited Derive de tetrahydroisoquinoline
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors

Also Published As

Publication number Publication date
KR20030060953A (ko) 2003-07-16
AU2002229546B2 (en) 2006-05-04
NO20032290D0 (no) 2003-05-21
MXPA03004534A (es) 2003-09-10
AU2954602A (en) 2002-06-03
PL366704A1 (en) 2005-02-07
GB0028483D0 (en) 2001-01-10
WO2002042277A1 (fr) 2002-05-30
PA8533401A1 (es) 2002-10-31
BG107839A (bg) 2004-06-30
JP2004520283A (ja) 2004-07-08
CA2428459A1 (fr) 2002-05-30
HUP0303007A2 (hu) 2003-12-29
NO20032290L (no) 2003-05-21
RU2265016C2 (ru) 2005-11-27
UY27033A1 (es) 2002-06-20
BR0115566A (pt) 2003-09-30
ECSP034618A (es) 2003-06-25
EP1339692A1 (fr) 2003-09-03
GT200100233A (es) 2002-07-04
SK7602003A3 (en) 2004-01-08
CN1476436A (zh) 2004-02-18
MA26966A1 (fr) 2004-12-20
NZ525550A (en) 2004-11-26
AR031763A1 (es) 2003-10-01
US6472404B1 (en) 2002-10-29
PE20020610A1 (es) 2002-07-13
CZ20031667A3 (cs) 2004-01-14
RU2003117468A (ru) 2005-01-27

Similar Documents

Publication Publication Date Title
AU1339302A (en) Biaryl compounds as serine protease inhibitors
AP2002002593A0 (en) Protease inhibitors
IL152830A0 (en) Arylmethylamine derivatives for use as tryptase inhibitors
PL362546A1 (en) Benzamide compounds as apo b secretion inhibitors
GB0125445D0 (en) Protease Inhibitors
SI1686119T1 (sl) Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
IL156064A0 (en) Vla-4 inhibitors
IL153661A0 (en) Piperidine compounds for use as ccr-3 inhibitors
AU2001247589A1 (en) Non-amidine containing protease inhibitors
AU2002211464A1 (en) Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors
AU6381701A (en) Bisamidino compounds as nhe-3 inhibitors
AU2001245764A1 (en) Novel compounds and compositions as protease inhibitors
GB9907683D0 (en) Substituted azetidin-2-ones as cysteine protease inhibitors
AU6989501A (en) Hiv integrase inhibitors
IL153421A0 (en) Protease inhibitors
SI1217002T1 (en) 2-(4-pyridinyl)-benzofurans as metalloprotease inhibitors
AU7847901A (en) Pyrrolidine derivatives as metalloprotease inhibitors
IL151250A0 (en) Difluorobutyric acid metalloprotease inhibitors
IL151087A0 (en) Protease inhibitors
AU2954602A (en) Novel compounds for use as hiv protease inhibitors
AU2001225373A1 (en) Urea compounds as inhibitors for vla-4
HUP0301964A3 (en) Protease inhibitors
AU2003287325A8 (en) N-cycloalkylglycines as hiv protease inhibitors
AU6407701A (en) Serine protease inhibitors
AU2002346812A1 (en) Use of 1-phenyl-oxazolidine-2-one compounds as protease m inhibitors